DE69739758D1 - Vakzine zur behandlung von lymphomen und leukämie - Google Patents

Vakzine zur behandlung von lymphomen und leukämie

Info

Publication number
DE69739758D1
DE69739758D1 DE69739758T DE69739758T DE69739758D1 DE 69739758 D1 DE69739758 D1 DE 69739758D1 DE 69739758 T DE69739758 T DE 69739758T DE 69739758 T DE69739758 T DE 69739758T DE 69739758 D1 DE69739758 D1 DE 69739758D1
Authority
DE
Germany
Prior art keywords
lymphoma
vaccine
leukemia
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69739758T
Other languages
English (en)
Inventor
Dan W Denney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genitope Corp
Original Assignee
Genitope Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genitope Corp filed Critical Genitope Corp
Priority claimed from PCT/US1997/007039 external-priority patent/WO1997041244A1/en
Application granted granted Critical
Publication of DE69739758D1 publication Critical patent/DE69739758D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
    • C12N9/003—Dihydrofolate reductase [DHFR] (1.5.1.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
DE69739758T 1996-05-01 1997-04-25 Vakzine zur behandlung von lymphomen und leukämie Expired - Lifetime DE69739758D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/644,664 US5776746A (en) 1996-05-01 1996-05-01 Gene amplification methods
US08/761,277 US5972334A (en) 1996-05-01 1996-12-06 Vaccines for treatment of lymphoma and leukemia
PCT/US1997/007039 WO1997041244A1 (en) 1996-05-01 1997-04-25 Vaccines for treatment of lymphoma and leukemia

Publications (1)

Publication Number Publication Date
DE69739758D1 true DE69739758D1 (de) 2010-03-25

Family

ID=24585869

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69739758T Expired - Lifetime DE69739758D1 (de) 1996-05-01 1997-04-25 Vakzine zur behandlung von lymphomen und leukämie

Country Status (4)

Country Link
US (5) US5776746A (de)
DE (1) DE69739758D1 (de)
TW (1) TW200519125A (de)
ZA (1) ZA973701B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999041403A1 (en) * 1998-02-12 1999-08-19 The Regents Of The University Of California Compositions for receptor/liposome mediated transfection and methods of using same
US6867154B1 (en) 1998-04-20 2005-03-15 Southern Mills, Inc. Patterned, flame resistant fabrics and method for making same
ID28040A (id) * 1998-05-19 2001-05-03 Avidex Ltd Reseptor sel t yang dapat larut
US6156514A (en) 1998-12-03 2000-12-05 Sunol Molecular Corporation Methods for making recombinant cells
ATE417106T1 (de) * 1999-03-12 2008-12-15 Aventis Pasteur Chlamydia antigene und deren korrespondierende dna fragmente und verwendungen davon
EP1192278A4 (de) * 1999-06-11 2003-05-28 Human Genome Sciences Inc 48 menschliche sekretierte proteine
US20060276629A9 (en) * 1999-12-17 2006-12-07 Hildebrand William H Purification and characterization of soluble human HLA proteins
US7521202B2 (en) * 1999-12-17 2009-04-21 The Board Of Regents Of The University Of Oklahoma Method and apparatus for the production of soluble MHC antigens and uses thereof
US20030166057A1 (en) * 1999-12-17 2003-09-04 Hildebrand William H. Method and apparatus for the production of soluble MHC antigens and uses thereof
US20060035338A1 (en) * 1999-12-17 2006-02-16 Pure Protein Llc Method and apparatus for the production of soluble MHC antigens and uses thereof
WO2002013861A2 (en) * 2000-08-11 2002-02-21 Favrille, Inc. Method and composition for altering a t cell mediated pathology
ES2401421T3 (es) * 2000-08-11 2013-04-19 Mmrgolbal, Inc. Método y ocmposición para alterar una patología mediada por células B
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
US20030130215A1 (en) * 2000-09-21 2003-07-10 Ryan James W. Isolated genomic polynucleotide fragments from chromosome 7
WO2002030964A2 (en) * 2000-10-10 2002-04-18 The Board Of Regents Of The University Of Oklahoma Comparative ligand mapping from mhc positive cells
US20070099182A1 (en) * 2000-10-10 2007-05-03 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US20050003483A1 (en) * 2000-10-10 2005-01-06 Hildebrand William H. Comparative ligand mapping from MHC class 1 positive cells
US20090062512A1 (en) * 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US20070026433A1 (en) 2001-03-09 2007-02-01 Hildebrand William H Epitope testing using soluble HLA
US20020122820A1 (en) * 2001-01-16 2002-09-05 Hildebrand William H. Soluble MHC artificial antigen presenting cells
WO2002069198A2 (en) * 2001-02-21 2002-09-06 The Board Of Regents Of The University Of Oklahoma Hla ligand database utilizing predictive algorithms and methods of making and using same
DE60223040T2 (de) * 2001-03-09 2008-07-31 The Board Of Regents Of The University Of Oklahoma, Norman Epitop-untersuchung mit hla
US20040126829A1 (en) * 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
WO2003062449A2 (en) * 2002-01-18 2003-07-31 The Trustees Of Columbia University In The City Of New York Methods of isolating specific cells of caenorhabditis elegans and obtaining genomic information therefrom
AU2003237493A1 (en) * 2002-01-23 2003-09-02 Cel-Sci Corporation Methods for treating diseases or conditions with peptide constructs
EP1531850B1 (de) * 2002-06-07 2012-02-22 ZymoGenetics, Inc. Verwendung von IL-21 und monoklonalem Antikörper zur Behandlung von fester Tumore
ATE382687T1 (de) * 2003-01-16 2008-01-15 Genencor Int Verfahren zur stellengerichteten mutagenese und gezielten randomisierung
KR100643122B1 (ko) * 2003-03-03 2006-11-10 주식회사 에스엔피 제네틱스 Ｈｂｖ진행/ｈｃｃ발생에 대한 감수성의 예측을 위한ｉｌ10 해플로타입의 용도
AU2004234377A1 (en) * 2003-04-25 2004-11-11 Immunex Corporation Inducers of recombinant protein expression
US20040259135A1 (en) * 2003-05-09 2004-12-23 Cleary Michael D. Biosynthetic labeling and separation of RNA
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
WO2005030931A2 (en) * 2003-09-23 2005-04-07 Favrille, Inc. Altering a b cell pathology using self-derived antigens in conjunction with specific-binding cytoreductive agent
WO2005044998A2 (en) * 2003-11-05 2005-05-19 Palingen, Inc. Enhanced b cell cytotoxicity of cdim binding antibody
US20050130897A1 (en) * 2003-12-11 2005-06-16 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
US7906180B2 (en) * 2004-02-27 2011-03-15 Molecular Imprints, Inc. Composition for an etching mask comprising a silicon-containing material
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
ES2732623T3 (es) 2005-01-06 2019-11-25 Innate Pharma Sa Tratamientos y métodos de combinación anti-KIR
US7790446B2 (en) * 2005-02-11 2010-09-07 Kosagen Cell Factory Oü Vectors, cell lines and their use in obtaining extended episomal maintenance replication of hybrid plasmids and expression of gene products
WO2008088301A2 (en) * 2005-04-26 2008-07-24 Corgentech, Inc. Inhibitors of dnaa activity
RU2295517C1 (ru) * 2005-06-24 2007-03-20 Институт проблем химической физики РАН (ИПХФ РАН) Производные дикарбоновых кислот, ингибиторы метастазов и средства, повышающие химиотерапевтическую активность противоопухолевых препаратов, способ усиления эффективности цитостатиков, способ ингибирования процесса метастазирования
US20070134249A1 (en) * 2005-12-08 2007-06-14 Genitope Corporation Combination therapy and antibody panels
ES2902063T3 (es) 2006-09-08 2022-03-24 Abbvie Bahamas Ltd Proteínas de unión a interleucina-13
WO2008051619A2 (en) * 2006-10-24 2008-05-02 Los Alamos National Security, Llc Vectors and methods for selecting open reading frames
EP1953222A1 (de) * 2007-01-24 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Verbesserung des Zellwachstums
AR072832A1 (es) * 2008-07-23 2010-09-22 Boehringer Ingelheim Pharma LINEAS DE CELULAS HOSPEDANTES DE PRODUCCION MEJORADA QUE CONTIENEN CONSTRUCCIONES DE VECTORES QUE COMPRENDEN UN CASETE DE EXPRESIoN DE DHFR (ENZIMA DIHIDROFOLATO REDUCTASA).
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
WO2010053518A2 (en) * 2008-10-29 2010-05-14 Sangamo Biosciences, Inc. Methods and compositions for inactivating glutamine synthetase gene expression
WO2011003633A1 (en) 2009-07-06 2011-01-13 Alize Pharma Ii Pegylated l-asparaginase
EP2548025A4 (de) 2010-03-17 2013-09-25 Univ Michigan Verwendung von phagenepitopen zur profilierung einer immunreaktion
WO2014036488A1 (en) 2012-08-31 2014-03-06 Biovest International, Inc. Methods for producing high-fidelity autologous idiotype vaccines
US10857219B2 (en) 2014-03-28 2020-12-08 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble HLA/M. tuberculosis-specific ligand complexes and methods of production and use thereof
US10174302B1 (en) 2017-06-21 2019-01-08 Xl-Protein Gmbh Modified L-asparaginase
CA3135175C (en) 2019-03-28 2022-10-18 Southern Mills, Inc. Flame resistant fabrics
US11891731B2 (en) 2021-08-10 2024-02-06 Southern Mills, Inc. Flame resistant fabrics
WO2023168397A1 (en) * 2022-03-04 2023-09-07 Sigma-Aldrich Co. Llc Metabolic selection via the asparagine biosynthesis pathway

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) * 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8601597D0 (en) * 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
FR2619719B1 (fr) 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5043270A (en) * 1989-03-31 1991-08-27 The Board Of Trustees Of The Leland Stanford Junior University Intronic overexpression vectors
US5270202A (en) * 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
EP0433900B1 (de) 1989-12-13 1995-09-20 Yeda Research And Development Company Limited Expression des rekombinanten Tumor-Nekrosisfaktor-Bindungsproteins I (TBP-I)
US20030072751A1 (en) * 1990-03-14 2003-04-17 Heribert Bohlen Idiotypic vaccination against b cell lymphoma
WO1994008601A1 (en) * 1992-10-14 1994-04-28 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of b cell lymphoma tumor resistance using idiotype/cytokine conjugates
US6235280B1 (en) * 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6632431B2 (en) * 2000-05-16 2003-10-14 New York University Anti-idiotypic antibody against FimH adhesion of uropathogenic type I-fimbriated Escherichia coli, compositions containing same and method for using same

Also Published As

Publication number Publication date
US5776746A (en) 1998-07-07
ZA973701B (en) 1998-02-04
US5972334A (en) 1999-10-26
US7208146B2 (en) 2007-04-24
US20020160006A1 (en) 2002-10-31
US7405060B2 (en) 2008-07-29
TW200519125A (en) 2005-06-16
US20040096452A1 (en) 2004-05-20
US7419660B1 (en) 2008-09-02

Similar Documents

Publication Publication Date Title
DE69739758D1 (de) Vakzine zur behandlung von lymphomen und leukämie
ATE363904T1 (de) Benzimidazol-2-carbamat zur behandlung viraler infektionen und von krebs
DE69739303D1 (de) Vorrichtung zur thermischen behandlung von gewebe
DE69732152D1 (de) Vorrichtung zur Behandlung von Kopfschmerzen
DE69312624D1 (de) Vorrichtung zur unterscheidung von tachykardien und fibrillationen und zur entsprechenden behandlung
DE69829921D1 (de) Vorrichtung zur Behandlung von Körpergewebe
DE69827424D1 (de) Vorrichtung zur gesteuerten thermischen Behandlung von Gewebe
DE69806801D1 (de) Galenische präparation zur prävention und behandlung von hepatokarzinomen
DE69711311D1 (de) Vorrichtung zur thermischen Behandlung von Gewebe
DE69220051T2 (de) Vorrichtung zur Behandlung von Getreide
ATA11989A (de) Mittel zur vorbeugung gegen und behandlung von parodontopathien
DE69506019T2 (de) Vorrichtung zur Behandlung von Schmerz
DE69727240D1 (de) Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
DE29808006U1 (de) Sprühvorrichtung zur Behandlung von Schnitt- und Fräskanten
ATE347372T1 (de) Vakzine zur behandlung von mycosen
DE29718503U1 (de) Gerät zur Behandlung von Tinitus und Hyperakusis
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
DE69834937D1 (de) Antibiotika zur behandlung von magengeschwuren
DE69510642D1 (de) Kombinierte Vorrichtung zur Behandlung von Modulen und Geräten und zur Verlegung von langgestreckten Gegenständen
ATE346840T1 (de) Aminoalkylphenol-derivate zur behandlung von depression und gedächtnis-funktionsstörung
NO985068L (no) Vaksiner for behandling av lymfom og leukemi
DE69806062T2 (de) Kombinationstherapie zur behandlung von aids
ATA84689A (de) Einrichtung zur behandlung von gasen
ATA93695A (de) Mittel zur behandlung von strahlenschäden

Legal Events

Date Code Title Description
8364 No opposition during term of opposition